<DOC>
	<DOCNO>NCT01290094</DOCNO>
	<brief_summary>This single arm , open label study assess efficacy safety compliance treatment Bonviva/Boniva ( ibandronate ) biphosphonate-naïve patient post-menopausal osteoporosis . Patients receive Bonviva/Boniva dose 3 mg intravenously every three month . Anticipated time study treatment 12 month follow-up 12 month .</brief_summary>
	<brief_title>A Study Bonviva/Boniva ( Ibandronate ) Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Female patient , &gt; 50 year age Diagnosed osteoporosis Bone mineral density &lt; minus 2.5 SD osteoporotic fracture At least 3 year menopause Impaired renal function Contraindication Calcium Vitamin D therapy Previous current treatment biphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>